UPDATE: Cowen Starts Apollo Endosurgery (APEN) at Outperform

Cowen analyst Jashua Jennings initiates coverage on Apollo Endosurgery (NASDAQ: APEN) with a Outperform rating and a price target of $13.00.

The analyst comments "We are initiating coverage of APEN at Outperform. Each of APEN's three key products is highly differentiated and has clear growth catalysts. We model a three-year revenue CAGR of 20% and gross margin improving to 62.5% in 2024, making APEN a standout among small-cap device names. Our target is $13, or 6.5 times our 2023 sales estimate of $87.5M."

For an analyst ratings summary and ratings history on Apollo Endosurgery click here. For more ratings news on Apollo Endosurgery click here.

Shares of Apollo Endosurgery closed at $7.64 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Colgate-Palmolive Company (CL) at Market Perform
• RBC Capital Starts Guardant Health (GH) at Outperform, 'Underpenetrated Market'
• Navan Inc (NAVN) PT Raised to $29 at TD Cowen After a 'Big Beat & Raise to Start FY27'